Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/rmdopen-2015-000162 http://scihub22266oqcxt.onion/10.1136/rmdopen-2015-000162 C4663453!4663453!26635968     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       RMD+Open 2015 ; 1 (1): ä Nephropedia Template TP {{tp|p=26635968|t=2015. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases |pdf=|usr=}}{{26635968}} gab.com Text Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases JO: RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=26635968 #FOAvip Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74?years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8?mg/kg every 4?weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales (p<0.05). Proximal muscle pain disappeared within 8?weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12?weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4?weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment. Twit Text FOAVip Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases ????RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=26635968 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26635968 #FOAvip English Wikipedia <ref>{{Cite pmid|26635968}}</ref> Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases #MMPMID26635968 Izumi K; Kuda H; Ushikubo M; Kuwana M; Takeuchi T; Oshima H RMD Open 2015[]; 1 (1): ä PMID26635968show ga Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74?years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8?mg/kg every 4?weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales (p<0.05). Proximal muscle pain disappeared within 8?weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12?weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4?weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment. äTocilizumab is effective against polymyalgia rheumatica: experience in(epmc).pdf DeepDyve Pubget Overpricing